ROCHESTER, N.Y.--(BUSINESS WIRE)--Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation biomedical technology, published a report written with the U.S. Food and Drug Administration (FDA) entitled “Biophan Technologies CRADA Workshop on the Safe Use of Implantable Medical Devices in Magnetic Resonance Imaging (MRI) Systems – Summary from Initial Workshop.” The paper was authored by Howard Bassen, Ph.D. of the FDA, Jeffrey Helfer, Biophan VP Engineering, and Andreas Melzer, M.D., CEO of Biophan Europe. The findings come from a recent workshop designed to research and define methods for measuring MRI safety of medical implants; the workshop was hosted by Biophan and the United States Food and Drug Administration’s (FDA) Office of Science and Engineering Laboratories (OSEL) in Rockville, Maryland.
